Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Anilides
  • Antineoplastic Agents
  • Breast Neoplasms
  • Nitriles
  • Receptors, Androgen
  • Receptors, Estrogen
  • Tosyl Compounds

abstract

  • AR was expressed in 12% of patients with ER/PgR-negative breast cancer screened for this trial. The CBR of 19% observed with bicalutamide shows proof of principle for the efficacy of minimally toxic androgen blockade in a select group of patients with ER/PgR-negative, AR-positive breast cancer.

publication date

  • October 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4086643

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-12-3327

PubMed ID

  • 23965901

Additional Document Info

start page

  • 5505

end page

  • 12

volume

  • 19

number

  • 19